Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety monitoring of Huachansu tablets
ChiCTR2300073452Phase 4Completed
- Sponsor
- Baoji Central Hospital
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cinobufacini, sponsored by Baoji Central Hospital. Primary endpoints: Adverse reaction incidence, Adverse reaction characteristics and 1 more. Started Jul 2023; status: completed.
02
Drugs
cinobufacini
Beyond the preview
Go deeper on ChiCTR2300073452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073452.